85
Participants
Start Date
June 30, 2022
Primary Completion Date
April 30, 2025
Study Completion Date
April 30, 2025
ABSK061
In the escalation part, patients will receive a single dose of oral ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in subsequent cycles (28-day cycles). The starting dose is 5 mg BID. In the expansion part, patients will each receive oral ABSK061 at the RDE in repeated 28-day cycles.
RECRUITING
Mary Crowley Cancer Research, Dallas
RECRUITING
Yuan LU, Shanghai
RECRUITING
The First Affiliated Hospital of Bengbu Medical College, Bengbu
NOT_YET_RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
NOT_YET_RECRUITING
Chongqing Daping Hospital, Chongqing
NOT_YET_RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Sun Yat-sen Memorial Hospital/ the Second Affiliated Hospital of Sun Yat-sen University, Guanzhou
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
NOT_YET_RECRUITING
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
The Affiliated Hospital of Inner Mongolia Medical University, Hohhot
RECRUITING
Xuzhou Center Hospital, Xuzhou
RECRUITING
First Hospital of Jilin University, Changchun
NOT_YET_RECRUITING
JILIN Cancer Hospital, Changchun
NOT_YET_RECRUITING
Yunnan Cancer Hospital, Yunnan
RECRUITING
Liaoning Province Cancer Hospital, Shenyang
NOT_YET_RECRUITING
The First Hospital of China Medical University, Shenyang
NOT_YET_RECRUITING
Shanghai Chest Hospital, Shanghai
RECRUITING
Chongqing University Cancer Hospital, Chongqing
RECRUITING
The Second Affiliated Hospital Zhejiang University School of Medicine, Hanzhou
Lead Sponsor
Abbisko Therapeutics Co, Ltd
INDUSTRY